01—Abstract
Summary
Summary of the 8-K filed April 17, 2026. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories (ABT) filed an 8-K on April 17, 2026 under Item 8.01 (Other Events) to disclose a proposed settlement of a consolidated shareholder derivative lawsuit, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation (N.D.
Illinois, Case No. 1:22-cv-5513). The suit, previously disclosed in Abbott's 10-Ks for fiscal 2024 and 2025, names certain current and former directors and officers and alleges breach of fiduciary duty for failing to oversee infant formula manufacturing and sale, plus federal securities law violations tied to misstatements about the same subject matter. On April 10, 2026, the court preliminarily approved the settlement and scheduled a final settlement hearing.
The settlement is non-monetary from Abbott's side in terms of payment to shareholders. Its principal term is that Abbott will maintain or adopt the corporate governance policies listed in Exhibit A to the stipulation and will commit the funds necessary to implement the governance elements. Lead Plaintiffs' counsel may request fees and expenses of up to $15.85 million, plus service awards of up to $15,000a per lead plaintiff, subject to court approval.
The defendants deny wrongdoing, and the settlement would release the claims covered by the stipulation, including those arising from the February 2022 powdered infant formula recall and the Sturgis, Michigan and Casa Grande, Arizona facilities. For investors, the filing is a litigation-resolution update rather than a financial disclosure. It contains no reported earnings impact or reserve amount.
The key dates are the May 18, 2026 deadline for shareholder objections and notices of intent to appear, and the June 4, 2026 final settlement hearing before Judge Sunil R. Harjani. Investors should note that the filing does not quantify the cost of the governance commitments, and the full terms are in the stipulation, which is available from the court.
02—Key points
Key Highlights
- Abbott disclosed (Item 8.01) that the court preliminarily approved a proposed settlement of a consolidated shareholder derivative lawsuit on April 10, 2026.
- The suit alleges directors and officers failed to oversee infant formula manufacturing and sale, and made misleading SEC-related statements about it.
- Core settlement term is corporate governance reform, including enhanced internal reporting and oversight for legal and regulatory compliance, with Abbott committing the necessary funds to implement it.
- Plaintiffs' counsel may request up to $15.85 million in fees and expenses, plus service awards of up to $15,000 per lead plaintiff, subject to court approval.
- Defendants deny all wrongdoing; the settlement is not an admission of liability.
- Shareholder objections must be received by May 18, 2026; the final settlement hearing is June 4, 2026, before Judge Sunil R. Harjani.
- The filing discloses no quantified financial impact, reserve, or earnings effect.
03—Questions
Frequently Asked Questions
Does this settlement involve a cash payment from Abbott to shareholders?
No payment to shareholders is described. The settlement's principal consideration is corporate governance reform. The filing's only quantified cost is the up-to-$15.85 million fee and expense request from plaintiffs' counsel, which is subject to court approval.
What claims are being released if the settlement is approved?
The release covers claims asserted or that could have been asserted in the consolidated action, related derivative actions, and related shareholder demands. It is broad and extends to the February 2022 powdered infant formula recall and the Sturgis, Michigan and Casa Grande, Arizona facilities.
Could this lawsuit have a material financial impact on Abbott?
The filing discloses no reserve or quantified exposure. Because the claims are derivative, any recovery would belong to Abbott, and the proposed resolution is governance-based. The filing gives no basis for estimating a financial effect, and the court has not yet approved the settlement.
What should shareholders do if they want to object?
Shareholders must submit a signed written objection with their name, address, phone number, proof of share ownership such as brokerage statements, and a detailed statement of objections. It must be received by May 18, 2026, by the court, plaintiffs' counsel, Abbott's counsel, and the individual defendants' counsel. Attendance at the June 4, 2026 hearing is optional.
When will the court decide whether to approve the settlement?
The court will consider objections and decide fairness at the final settlement hearing on June 4, 2026, at 9:30 a.m. in Chicago. The notice warns that the hearing date may change without further notice, so attendees should confirm it with lead plaintiffs' counsel.
04—Continue